Fig. 6

TMEM160 plays a crucial role in tumor immune evasion. A, B To establish CDX models, nude mice were subcutaneously injected with HCT116 cells that had been stably transfected with LV-ShTMEM160#1 or LV-ShScr. C, D In the LV-TMEM160#1 group, the tumor volume and weight were lower than those in the control group (mean ± SEM, n = 6/group). E, F To establish CDX models, BALB/c mice were subcutaneously injected with CT26 cells that had been stably transfected with LV-ShTMEM160#1 or LV-ShScr. G, H In the LV-TMEM160#1 group, the tumor volume and weight were markedly lower than those in the control group (mean ± SEM, n = 6/group). I, J Western blotting and IHC were conducted to detect the protein levels of TMEM160 and PD-L1 in tumor tissues obtained from subcutaneous CDX models constructed by HCT116 cells. K, L The protein levels of TMEM160 and PD-L1 and the infiltration of CD8 + T lymphocytes in subcutaneous CDX models constructed from CT26 cells were determined by western blotting and IHC